WE ARE SATURNUS BIO
One in three patients living with heart failure has a monogenic mutation that drives disease.
We are addressing genetic drivers of heart failure using targeted, non-viral gene-modulating therapies.
Our vision is to transform the lives of millions with a portfolio of first-in-class disease-modifying medicines.
Our team of life science professionals has decades of experience discovering and developing medicines for patients living with cardiovascular and genetic diseases.
Leadership Team
-
Rick Dewey, MD
CO-FOUNDER AND CEO
-
Russell Miller, PhD
HEAD OF DISCOVERY RESEARCH
-
Eric Lim, PhD
HEAD OF COMPUTATIONAL BIOLOGY AND DATA SCIENCE
-
Christian Kunz, PhD
VP BIOLOGICS DISCOVERY, RIDGELINE DISCOVERY
Founding Advisors
-
Euan Ashley, MRCP DPhil
CO-FOUNDER AND SAB CHAIR
-
Adrian Krainer, PhD
-
James Ware, MD PhD
-
Morrie Birnbaum, MD PhD
-
Rob Burke, PhD
-
Eric Green, MD PhD
Board of Directors
-
Rick Dewey, MD
CO-FOUNDER AND CEO
-
Carlo Rizzuto, PhD
BOARD DIRECTOR, VERSANT VENTURES
-
Nigel Sheail
BOARD DIRECTOR, VERSANT VENTURES
-
Arvind Rajpal, PhD
BOARD DIRECTOR, EMD SERONO
-
Matthias Müllenbeck, MBA
BOARD OBSERVER, EMD SERONO
-
Aftab Kherani, MD
HAMMARSKJOLD BOARD OBSERVER
Investors
